Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag versus placebo for chemotherapy-induced thrombocytopenia
2025-524209-34-00Phase 3Authorised
- Sponsor
- Hengrui Therapeutics
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) comparing Hetrombopag olamine with Placebo (2 arms). Primary endpoints: Pharmacokinetic parameters in Part A and Treatment responder proportion. Planned start May 2026; status: authorised.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on 2025-524209-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524209-34-00.